New protocol from Japan enables high-affinity monoclonal antibody production from single B cells in 6 days.
Cost-effective and works across antibody types, including for SARS-CoV-2 spike protein.
Chinese researchers:
GZNL-P36 is a promising drug candidate for COVID-19 targeting a conserved viral enzyme, showing broad antiviral and anti-inflammatory effects.
Mouse trials: it reduces viral load, inflammation, and lung damage
Researchers at The University of Hong Kong developed TMP1, an oral drug blocking coronavirus entry and replication.
Tested in mice and hamsters, it was effective against SARS-CoV-2 variants and drug-resistant strains.
NZ-804, a new oral drug, stops SARS-CoV-2 replication in animal models.
Unlike current treatments, it’s safe, low-cost, and has a high barrier to resistance.
My note: Would like to see study on this drug with endpoints like time to recovery, severity of symptoms, long-term follow-up for post-acute symptoms. Not holding my breath. This is, after all, Giliad, the maker of remdesivir. Still, potential early treatment option here:
465 adults received either obeldesivir or a placebo for 5 days. The results showed that those on obeldesivir had a 0% hospitalization rate and lower mortality compared to 0.5% in the placebo group.
Patients taking obeldesivir also experienced quicker symptom relief and greater reductions in the virus levels. Overall, the drug was found to be generally safe and well-tolerated.
Anti-Viral Impact of Metformin “When AMPK was activated in Calu3 and Caco2 cell lines using metformin, there was a remarkable suppression of SARS-CoV-2 infectious titers, with up to 99% reduction observed in infected cells.”
Metformin suppresses SARS-CoV-2 in cell culture
Next generation medicines in fight against Covid:
Focusing specifically on the receptor-binding domain (RBD) rather than the entire SARS-CoV-2 spike protein provides enhanced, long-lasting protection against viral mutations
Prospective study in France shows Sulfodyne®, a natural antioxidant, reduces SARS-CoV-2 replication and inflammation.
Outperformed other treatments, lowering viral load and symptoms in infected mice.
Promising COVID-19 therapeutic.
“INCLUSION OF MEGLUMINE ACRIDONE ACETATE (MA): CYCLOFERON
Study on hyperbaric oxygen therapy (HBOT) for Long Covid
After 3 months, 65% reported improved quality of life, especially in cognitive functions, but 15% experienced worsening symptoms.
